References
- Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndrome. J Rheumatol. 1991;18(5):721–7.
- Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford). 2004;43(5):626–32.
- de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Lévesque H, et al. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken). 2011;63(8):1188–94.
- Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica. 2009;94(4):449–51.
- Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Heamatol. 1995;91(2):403–8.
- Hamblin TJ. Myelodysplasia. Br J Hosp Med. 1987;38(6):558–61.
- Giannouli S, Kanellopoulou T, Voulgarelis M. Myelodysplasia and autoimmunity. Curr Opin Rheumatol. 2012;24(1):97–102.
- Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol. 1996;33(2):150–62.
- Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol. 2011;38(5):667–72.
- Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, Voulgarelis M. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis. 2004;63(5):578–82.
- Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4 + CD25high Foxp3 + regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007;110:847–50.
- Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145:64–72.
- Cuende E, Guinea J, Ortiz de Urbina F, Torrabadella S, Templado JA, Vesga JC. Seronegative oligoarthritis in the course of refractory anaemia with excess blasts. Rheumatology (Oxford). 1999;38(4):373–5.
- Farmakis D, Polymeropoulos E, Polonifi A, Deftereos S, Giakoumi X, Floudas H, et al. Myelodysplastic syndrome associated with multiple autoimmune disorders. Clinical Rheumatol. 2005;24(4):428–30.
- Pipitone N, Masini L, Salvarani C. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade. Clin Exp Rheumatol. 2006;24(2 Suppl 41):31–4.
- Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol. 2011;153(5):664–5.